WallStSmart

Semilux International Ltd. Ordinary Shares (SELX)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 123% more annual revenue ($258.90M vs $116.23M). ZEPP leads profitability with a -15.5% profit margin vs -119.7%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

SELX

Avoid

23

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for SELX.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SELX1 strengths · Avg: 8.0/10
Price/BookValuation
2.3x8/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

SELX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.93M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-86.6%2/10

ROE of -86.6% — below average capital efficiency

Revenue GrowthGrowth
-24.6%2/10

Revenue declined 24.6%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : SELX

The strongest argument for SELX centers on Price/Book.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : SELX

The primary concerns for SELX are EPS Growth, Market Cap, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

SELX profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 23/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Semilux International Ltd. Ordinary Shares

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Semilux International Ltd. (SELX) is a prominent player in the advanced lighting solutions sector, recognized for its commitment to innovation and sustainability across commercial, industrial, and residential markets. With a comprehensive portfolio of high-performance, energy-efficient lighting products that meet stringent environmental standards, Semilux is well-positioned to thrive in the rapidly growing smart lighting industry. Led by an experienced management team, the company is strategically expanding its global footprint to leverage the surging demand for sustainable illumination, underscoring its dedication to pioneering technology and environmentally conscious practices.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?